An interventional study of Online LEND Intervention in Dementia, Neuro-Degenerative Disease and Alzheimer Disease, sponsored by University of Nottingham. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by University of Nottingham · Not applicable, Interventional, and Supportive care
Among 261 studies in Alzheimer Disease with a site in United Kingdom — 43 open to participants now, 69 under way, 26 of them phase 3. Alzheimer Disease · United Kingdom.
Among the 261 studies in Alzheimer Disease with a site in United Kingdom, this one is the 173rd largest by planned enrollment of the 226 interventional ones that give a count, is one of 16 that started in 2025, is one of 22 with no phase, reaches primary completion later than 51 of the 68 other live ones, and was the 258th registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
Browse Alzheimer Disease studies →43 of the 261 studies in Alzheimer Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 7 more countries
Denali Therapeutics Inc. · Sites in United Kingdom
Sanofi · Sites in United Kingdom, United States, Australia and 4 more countries
University College, London · Sites in United Kingdom
University of Plymouth · Sites in United Kingdom
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
261 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 84 · Phase 3 101 · Phase 4 3
First in 1999; this study’s year is marked. 16 started in 2025.
This study's planned enrollment of 60 is below the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Median enrollment 280 across the 226 interventional studies, 550 across the 35 observational. Of the 179 that completed or were terminated, 92 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 261 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
16 of the studies in Alzheimer Disease with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
Among the 261 studies in Alzheimer Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing the digital Online LEND Intervention, assessing its usability and acceptability, and conducting a feasibility study within NHS memory assessment and community services. Activities across the first three WPs include interviews, focus groups, user-testing sessions, engagement evaluation interviews, and a two-arm randomised feasibility trial using a range of outcome measures. Findings from this stage will inform refinement of the intervention and determine the feasibility of progressing to a future randomised controlled trial (RCT) of the Online LEND Intervention. WP4 is the Online LEND Intervention two-arm RCT. WP5 involves dissemination. The protocol for WP4 and 5 have not yet been developed and rely on results from WP1-3.
Study Overview The Lived Experience Narratives in Dementia (LEND) Programme is a five-year NIHR-funded research programme designed to develop, optimise, and evaluate a novel digital intervention that delivers personalised lived-experience narratives to people living with dementia and their carers. The ultimate goal is to improve wellbeing and quality of life by providing accessible, relatable, and culturally diverse narratives that promote hope, self-efficacy, independence, and emotional support.
Packages (WP) 1-3, includes theory development (WP1), intervention development (WP2), and a randomised controlled feasibility study with long-term follow-up interviews (WP3).
LEND prioritises inclusion of under-served communities, including Black and South Asian groups, LGBT+ communities, people with young-onset dementia, and people with rarer dementias (see LEND WP1-3 Protocol v1.0 CLEAN).
WORK PACKAGE 1: Development of LEND Theory WP1 develops the theoretical foundations that shape the design and content of the LEND digital intervention. It consists of five interconnected sub-work packages, each addressing a different element of user experience, narrative relevance, and contextual factors affecting engagement.
WP1.1: Online or Paper Survey (WP1.1O / WP1.1P) Purpose: To understand how people living with dementia and carers use social media, technology, and online resources over time.
Design: A continuous cross-sectional survey, recruiting ≥300 participants per year over five years (minimum n=1,500 total) LEND WP1-3 Protocol v1.0 CLEAN
Focus:
WP1.2: Semi-Structured Interviews Purpose: To explore how lived-experience narratives may benefit people living with dementia and carers, informing LEND theory.
Sample: n=30 (15 people with dementia; 15 carers) LEND WP1-3 Protocol v1.0 CLEAN
Focus:
WP1.3a: Narrative Impact Validation Purpose: To test how participants engage with up to five lived-experience narratives selected from an initial pool of \~30 narratives, including those from ethnic minority and under-served groups.
Sample: n=40 (20 people with dementia; 20 carers) LEND WP1-3 Protocol v1.0 CLEAN
Focus:
WP1.3b: Narrative Rating Purpose: To develop a categorisation framework for dementia narratives based on user ratings and feedback.
Sample: Repeat measures from WP1.3a.
Focus:
WP1.4: Focus Groups Purpose: Conducted in collaboration with the Centre for Ethnic Health Research, WP1.4 prioritises inclusion of Black, South Asian, and other under-served communities.
Sample: Four focus groups (n=40 total) LEND WP1-3 Protocol v1.0 CLEAN
Focus:
WP1.5: Discrete Choice Experiment (DCE) Purpose: To determine which narrative features are most valued by people with dementia, carers, and the general public.
Sample:
Focus:
WORK PACKAGE 2: Development of LEND Intervention WP2 focuses on building the digital intervention through iterative, user-centred development.
WP2.3: Development of the LEND Digital Intervention WP2.3 is a multi-phase iterative development process consisting of workshops, prototype development, usability testing, accessibility refinement, and preparation for feasibility evaluation.
Phase 1: Co-production Workshops (Months 10-12)
Using LEAP (Lived Experience Advisory Panel) members and developers:
Key Features of Intervention (developed across WP2.3):
WORK PACKAGE 3: Feasibility Study and Long-Term Impact WP3 evaluates feasibility, acceptability, and preliminary signals of impact in preparation for a full-scale RCT.
WP3.1: Randomised Controlled Feasibility Study
Design:
Outcome Measures (all self-report via LEND Portal):
Primary outcomes include:
Secondary outcomes include:
Feasibility Outcomes:
WP3.2: Long-Term Impact Interviews Purpose: To evaluate longer-term influence of the LEND intervention among those who received it in WP3.1.
Sample: n=20
Timing:
Focus:
Integrated Purpose of WP1-3
Collectively, these work packages:
WP4 and WP5 will be determined following the evaluation of WP1-3.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 60 is below the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
General Inclusion Criteria (apply across WP1-WP3)
General Exclusion Criteria (apply across WP1-3)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in WP3, the feasibility trial, are allocated to this arm receive access to the LEND digital intervention. The intervention consists of a web-based platform that provides personalised lived-experience narratives curated for people with dementia and their family carers. Content includes written, audio, and video narratives covering themes such as coping strategies, identity, emotions, daily living, social relationships, and adjusting to diagnosis. Participants are able to browse and select narratives; receive recommendations based on preferences; bookmark or rate content; and use accessibility features designed to support cognitive needs, including simplified navigation, adjustable text, and audio playback. The intervention is used independently at home for 4 to 6 weeks, with no minimum usage requirement. Participants also complete baseline and follow-up outcome measures through the integrated LEND Portal prior to randomisation.
Behavioral: Online LEND Intervention
Participants randomised to this arm continue to receive their standard care and support as normally provided. This may include by NHS Memory Assessment Services, community mental health teams, primary care, and other relevant voluntary-sector and non voluntary-sector organisations. They do not receive access to the Online LEND Intervention during the feasibility study period. Prior to randomisation, participants complete the same baseline outcome measures. Access to the LEND portal, but not the Online LEND Intervention, is continued as follow-up outcome measures are required after 6 months period, paralleling the intervention arm.
The Online LEND Intervention is a web-based platform that provides personalised lived-experience narratives for people with dementia and their carers. It aims to support wellbeing, confidence, and self-efficacy by offering relatable stories from others with similar experiences. The final design is still in development but is expected to include personalised recommendations, simplified navigation, adjustable text, audio playback, captioning, and content warnings. Users will be able to bookmark, rate, or hide stories and access the intervention independently at home over a 4 to 6-week period. The platform will be accessed via the secure LEND Portal, where participants also complete study measures. LEND does not provide clinical advice; it offers supportive, ethically reviewed narratives to promote connection and empowerment.
Quality of Life (QoL-AD)
The Quality of Life in Alzheimer's Disease (QoL-AD) scale is a validated measure captures wellbeing across multiple domains including mood, relationships, daily activities, memory, and overall life satisfaction. The feasibility study will assess completeness of data, variability, and acceptability of QoL-AD as the primary endpoint for a future definitive RCT.
Time frame: Baseline and Six Months
Mental Wellbeing (SWEMWBS)
The Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS). This seven-item scale assesses emotional functioning, optimism, and psychological wellbeing. The feasibility study will evaluate suitability, recruitment, retention, and response characteristics of SWEMWBS as the primary carer outcome for the full trial.
Time frame: Baseline and Six Months
Engagement and Independence in Dementia Questionnaire (EID-Q)
For people with dementia only. Assesses engagement in meaningful activities, independence, autonomy, and perceived capabilities in daily life.
Time frame: Baseline and Six Months
Rosenberg Self-Esteem Scale - Brief Version (RSES)
For both people with dementia and family carers. Measure of global self-esteem and self-worth.
Time frame: Baseline and Six Months
General Self-Efficacy Scale (GSES)
For both people with dementia and family carers. Evaluates confidence in ability to cope with challenges, problem-solve, and exert control over important aspects of life.
Time frame: Baseline and Six Months
Caregiver Self-Efficacy Scale (CSES)
For Family carers only. Assesses carers' perceived ability to manage caregiving tasks, access support, and maintain personal wellbeing.
Time frame: Baseline and Six Months
Zarit Burden Interview - Short Version (ZBI-12)
For family carers only. Measures subjective caregiver burden, including emotional strain, role stress, and perceived overload.
Time frame: Baseline and Six Months
EQ-5D-5L
People with dementia and carers. Assesses health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time frame: Baseline and Six Months
ICECAP-O (ICEpop CAPability Measure for Older People)
People with dementia only. Evaluates broader wellbeing and capability across domains including attachment, security, role, enjoyment, and control.
Time frame: Baseline and Six Months
Adult Hope Scale (AHS)
For people with dementia and carers. Measures goal-directed thinking, including pathways (planning routes to goals) and agency (motivation to pursue goals).
Time frame: Baseline and Six Months
Client Service Receipt Inventory (CSRI)
For people with dementia and carers. Captures service use, support needs, and associated costs from both health and social care perspectives.
Time frame: Baseline and Six Months
Plan to share: No — Only anonymised data will be shared for the purposes of analysis and interpretation.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2029, 40 months after the start.
Of 882 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 40 months is above that.
Counting every sponsor, half of 959 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.